U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H22N2O
Molecular Weight 294.3908
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VINBURNINE, (±)-

SMILES

[H][C@]12N3CCC[C@@]1(CC)CC(=O)N4C5=CC=CC=C5C(CC3)=C24

InChI

InChIKey=WYJAPUKIYAZSEM-MOPGFXCFSA-N
InChI=1S/C19H22N2O/c1-2-19-9-5-10-20-11-8-14-13-6-3-4-7-15(13)21(16(22)12-19)17(14)18(19)20/h3-4,6-7,18H,2,5,8-12H2,1H3/t18-,19+/m1/s1

HIDE SMILES / InChI

Molecular Formula C19H22N2O
Molecular Weight 294.3908
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Vinburnine is a nutritional product, which is semi-synthesized from vincamine. It is a peripheral vasodilator with cerebral activities that also act as a cerebral metabolic stimulant and appears to be able to relax the smooth muscle cells within the walls of blood vessels. Some evidence also suggests that vinburnine stimulates acetylcholine neurotransmission. Acetylcholine is a very important neurotransmitter responsible for a number of cognitive functions, such as memory and learning.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P08172
Gene ID: 1129.0
Gene Symbol: CHRM2
Target Organism: Homo sapiens (Human)
68.9 µM [Kd]
Target ID: P11229
Gene ID: 1128.0
Gene Symbol: CHRM1
Target Organism: Homo sapiens (Human)
7.54 µM [Kd]
Target ID: P20309
Gene ID: 1131.0
Gene Symbol: CHRM3
Target Organism: Homo sapiens (Human)
6.67 µM [Kd]
Target ID: P08173
Gene ID: 1132.0
Gene Symbol: CHRM4
Target Organism: Homo sapiens (Human)
23.7 µM [Kd]
Target ID: acetylcholine neurotransmission
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CERVOXAN

Approved Use

Cerebrovascular diseases
PubMed

PubMed

TitleDatePubMed
Metabolism of vincamine in the rat in vivo and in vitro.
1980
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
1997 Jul
Patents

Sample Use Guides

In Vivo Use Guide
The recommended dosage is 60 mg taken twice a day.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Different concentrations of the drugs: vincamine, vinpocetine and eburnamonine (VINBURNINE) (4, 20 and 100 µM) induced minimal stimulation of the ATPase activity of the Bcrp and Pgp membrane transporters. The relative metabolic stability of eburnamonine compared to the other alkaloids suggests the use of eburnamonine or its derivatives as lead compounds for the development of antitumor and nootropic agents that need to cross the BBB and produce their pharmacological effects in the CNS.
Different concentrations of the three drugs, vincamine, vinpocetine, and eburnamonine, (4, 20 and 100 uM) induced minimal stimulation of the ATPase activity of the Bcrp and Pgp membrane transporters.
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:53:15 GMT 2023
Edited
by admin
on Sat Dec 16 08:53:15 GMT 2023
Record UNII
64UB2942IE
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VINBURNINE, (±)-
Common Name English
EBURNAMENIN-14(15H)-ONE, (±)-
Systematic Name English
DL-EBURNAMONINE
Common Name English
VINCANORINE
Common Name English
(±)-VINCAMONE
Common Name English
(±)-EBURNAMONINE
Common Name English
EBURNAMONINE (±)-FORM [MI]
Common Name English
Code System Code Type Description
WIKIPEDIA
Eburnamonine
Created by admin on Sat Dec 16 08:53:15 GMT 2023 , Edited by admin on Sat Dec 16 08:53:15 GMT 2023
PRIMARY
FDA UNII
64UB2942IE
Created by admin on Sat Dec 16 08:53:15 GMT 2023 , Edited by admin on Sat Dec 16 08:53:15 GMT 2023
PRIMARY
MERCK INDEX
m4804
Created by admin on Sat Dec 16 08:53:15 GMT 2023 , Edited by admin on Sat Dec 16 08:53:15 GMT 2023
PRIMARY Merck Index
CAS
2580-88-3
Created by admin on Sat Dec 16 08:53:15 GMT 2023 , Edited by admin on Sat Dec 16 08:53:15 GMT 2023
PRIMARY
PUBCHEM
71203
Created by admin on Sat Dec 16 08:53:15 GMT 2023 , Edited by admin on Sat Dec 16 08:53:15 GMT 2023
PRIMARY